These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 10901381)
41. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Wu XX; Ogawa O; Kakehi Y Int J Oncol; 2004 Jun; 24(6):1489-97. PubMed ID: 15138592 [TBL] [Abstract][Full Text] [Related]
42. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). Leu YL; Roffler SR; Chern JW J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293 [TBL] [Abstract][Full Text] [Related]
43. Ultrasound Enhances ZD2767P-Carboxypeptidase G2 against Chemoresistant Ovarian Cancer Cells by Altering the Intracellular Pharmacokinetics of ZD2767D. Liu Q; Zhong X; Zhang Y; Li X; Qian G; Yu T Mol Pharm; 2020 Jun; 17(6):1922-1932. PubMed ID: 32302486 [TBL] [Abstract][Full Text] [Related]
44. Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Schnelldorfer T; Gansauge S; Gansauge F; Schlosser S; Beger HG; Nussler AK Cancer; 2000 Oct; 89(7):1440-7. PubMed ID: 11013356 [TBL] [Abstract][Full Text] [Related]
45. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy. Mancini L; Davies L; Friedlos F; Falck-Miniotis M; Dzik-Jurasz AS; Springer CJ; Leach MO; Payne GS NMR Biomed; 2009 Jun; 22(5):561-6. PubMed ID: 19259950 [TBL] [Abstract][Full Text] [Related]
46. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy. Günther M; Waxman DJ; Wagner E; Ogris M Cancer Gene Ther; 2006 Aug; 13(8):771-9. PubMed ID: 16543915 [TBL] [Abstract][Full Text] [Related]
47. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Yang B; Keshelava N; Anderson CP; Reynolds CP Cancer Res; 2003 Apr; 63(7):1520-6. PubMed ID: 12670899 [TBL] [Abstract][Full Text] [Related]
48. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Morgan AS; Sanderson PE; Borch RF; Tew KD; Niitsu Y; Takayama T; Von Hoff DD; Izbicka E; Mangold G; Paul C; Broberg U; Mannervik B; Henner WD; Kauvar LM Cancer Res; 1998 Jun; 58(12):2568-75. PubMed ID: 9635580 [TBL] [Abstract][Full Text] [Related]
50. Production of Long-Acting CNGRC-CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment. Al-Mansoori L; Al Qahtani AD; Elsinga P; Goda SK Technol Cancer Res Treat; 2021; 20():15330338211057371. PubMed ID: 34802309 [No Abstract] [Full Text] [Related]
51. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo. Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645 [TBL] [Abstract][Full Text] [Related]
52. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Anderson CP; Reynolds CP Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530 [TBL] [Abstract][Full Text] [Related]
53. Identification of prodrug, active drug, and metabolites in an ADEPT clinical study. Springer CJ; Poon GK; Sharma SK; Bagshawe KD Cell Biophys; 1993; 22(1-3):9-26. PubMed ID: 7889545 [TBL] [Abstract][Full Text] [Related]
54. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. Springer CJ; Niculescu-Duvaz I; Pedley RB J Med Chem; 1994 Jul; 37(15):2361-70. PubMed ID: 8057284 [TBL] [Abstract][Full Text] [Related]
55. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273 [TBL] [Abstract][Full Text] [Related]
56. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634 [TBL] [Abstract][Full Text] [Related]
57. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. Schwartz PS; Chen CS; Waxman DJ Cancer Gene Ther; 2003 Aug; 10(8):571-82. PubMed ID: 12872138 [TBL] [Abstract][Full Text] [Related]
58. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Armstrong JS; Steinauer KK; Hornung B; Irish JM; Lecane P; Birrell GW; Peehl DM; Knox SJ Cell Death Differ; 2002 Mar; 9(3):252-63. PubMed ID: 11859408 [TBL] [Abstract][Full Text] [Related]
59. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798 [TBL] [Abstract][Full Text] [Related]
60. Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Kito M; Akao Y; Ohishi N; Yagi K; Nozawa Y Biochem Biophys Res Commun; 2002 Mar; 291(4):861-7. PubMed ID: 11866444 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]